CONgenital Cytomegalovirus: Efficacy of antiviral treatment in a non-Randomized Trial with historical control group CONgenitaal Cytomegalovirus.

Trial Profile

CONgenital Cytomegalovirus: Efficacy of antiviral treatment in a non-Randomized Trial with historical control group CONgenitaal Cytomegalovirus.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2015

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Cytomegalovirus infections; Hearing loss
  • Focus Therapeutic Use
  • Acronyms CONCERT-2
  • Most Recent Events

    • 20 Jun 2015 Planned End Date changed from 1 Jan 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
    • 20 Jun 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
    • 06 Dec 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT02005822).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top